Six proposals were not heard during the Coordination and Maintenance committee meeting.
The Coordination and Maintenance Committee Meeting was held March 9 – 10, 2021. The meeting began with discussion of the ICD-10-PCS topics. There were six proposals that were not discussed during the meeting which were therapeutic administration of drugs/substances. This article will review the six proposals. Remember that all comments for all procedure topics are due April 9, 2021. The comments should be sent to ICDProcedureCodeRequest@cms.hhs.gov.
The first proposal was for the administration of Amivantamab which is used to treat epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer with Exon20 insertions. The five-year survival rate is 8 percent with this type of cancer. This drug is a fully human bispecific antibody that binds to the extracellular domains of the epidermal growth factor and mesenchymal epithelial transition (MET). It is administered on a 28-day cycle on an outpatient basis. Patients may need to be administered if admitted for other complications of the disease. This drug has been designated as a breakthrough therapy and is currently working through clinical trials.
The second proposal is for the administration of Ciltacabtagene Autoleucel which is a B-cell maturation Antigen Directed CAR T-cell Therapy. This drug treats relapsed/refractory multiple myeloma. It takes approximately 57 days from registration to complete the initial round of therapy. There is a PCS code for CAR T-cell therapy, but not specific to this type of therapy.
The third proposal is ENSPRYNG (satralizumab mwge) which is a humanized IgG2 monoclonal antibody which is used for treating Neuromyelitis Optica Spectrum Disorder (NMOSD). Patients with this disorder relapsed 60% within one year and 90 percent within three years. These patients required wheelchairs (50 percent) and could be functionally blind (62percent). In the study, there was significant reduction in relapse. This medication is given subcutaneously as an inpatient or outpatient. After a loading dose, the medication is administered every four weeks.
The fourth proposal is administration of Trilaciclib which is a myelopreservation therapy. The goal of this therapy is to mitigate chemotherapy induced myelosuppression in extensive non-small cell lung cancer patients. Trilaciclib has been granted FDA breakthrough therapy status. This medication is administered intravenously or via central line. Patients are treated with four cycles of 21-day therapy. The patient is given chemotherapy with Trilaciclib days 1 – 3 followed by 18 days treatment free. One inpatient admission is expected, but the medication can be administered as an inpatient or outpatient.
The fifth proposal is administration of ZEPZELCA (lurbinectedin) which is a transcription inhibitor for patients with metastatic small cell lung carcinoma. This is a second line option whose cancer has progressed while on traditional chemotherapy. This medication has been approved by the Federal Drug Administration (FDA). The schedule for this medication is every 21 days. It can be administered on an inpatient or outpatient basis.
The last proposal is the transfusion of pathogen reduced cryoprecipitated fibrinogen complex (PRCFC) which is used to treat massive bleeding when patient is fibrinogen deficient. This substance is not the same as the usual cryoprecipitate. This substance has been approved by the FDA and was awarded breakthrough device designation. PRCFC is treated by INTERCEPT Blood System which inactivates pathogens to reduce transfusion transmitted infections (TTI). This product has a five-day at room temperature shelf-life.
These six drugs/products have requested New Technology Add-On Payment (NTAP) which provides additional reimbursement to the Medicare-Severity Diagnosis Related Group (MS-DRG). In proposed rule for Inpatient Prospective Payment System (IPPS) FY22, a preliminary recommendation will be published. These procedure codes are being considered for FY22 which begins Oct. 1, 2021.
Programming Note: Listen to Laurie Johnson report this story live today during Talk Ten Tuesdays, 10 a.m. Eastern.
The Coordination and Maintenance (C&M) Committee meeting was held on Sept. 12 and 13. The meeting began with the procedure proposals, which were followed by
The next Coordination and Maintenance (C&M) Committee meeting will be held on Sept. 12 and 13 . This meeting will be virtual, and you must
Please log in to your account to comment on this article.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Sepsis remains one of the most frequently denied and contested diagnoses, creating costly revenue loss and compliance risks. In this webcast, Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, provides practical, real-world strategies to align documentation with coding guidelines, reconcile Sepsis-2 and Sepsis-3 definitions, and apply compliant queries. You’ll learn how to identify and address documentation gaps, strengthen provider engagement, and defend diagnoses against payer scrutiny—equipping you to protect reimbursement, improve SOI/ROM capture, and reduce audit vulnerability in this high-risk area.
Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY26 IPPS, including new ICD-10-CM/PCS codes, CCs/MCCs, and MS-DRGs, plus insights, analysis and answers to your questions from two of the country’s most respected subject matter experts.
Get clear, practical answers to Medicare’s most confusing regulations. Join Dr. Ronald Hirsch as he breaks down real-world compliance challenges and shares guidance your team can apply right away.
Federal auditors are zeroing in on Inpatient Rehabilitation Facility (IRF) and hospital rehab unit services, with OIG and CERT audits leading to millions in penalties—often due to documentation and administrative errors, not quality of care. Join compliance expert Michael Calahan, PA, MBA, to learn the five clinical “pillars” of IRF-PPS admissions, key documentation requirements, and real-life case lessons to help protect your revenue.
During this essential RACmonitor webcast Michael Calahan, PA, MBA Certified Compliance Officer, will clarify the rules, dispel common misconceptions, and equip you with practical strategies to code, document, and bill high-risk split/shared, incident-to & critical care E/M services with confidence. Don’t let audit risks or revenue losses catch your organization off guard — learn exactly what federal auditors are looking for and how to ensure your documentation and reporting stand up to scrutiny.
Learn how to navigate the proposed elimination of the Inpatient-Only list. Gain strategies to assess admission status, avoid denials, protect compliance, and address impacts across Medicare and non-Medicare payors. Essential insights for hospitals.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
